Covert strokes prior to Alzheimer’s disease onset accelerate peri-lesional pathology but not cognitive deficits in an inducible APP mouse model

Mingzhe Liu,Tina L Beckett,Lynsie A M Thomason,Adrienne Dorr,Bojana Stefanovic,JoAnne McLaurin,Tina L. Beckett,Lynsie A.M. Thomason
DOI: https://doi.org/10.1016/j.brainres.2020.147233
IF: 3.61
2021-03-01
Brain Research
Abstract:<p>It is estimated that up to 1 in 3 healthy middle-aged adults will have had a covert stroke during their lifetime. Furthermore, post-stroke, survivors are more than twice as likely to develop dementia. In the present study, we aimed to model the impact of focal subclinical ischemia prior to the onset of AD pathogenesis in a preclinical model. We utilized endothelin-1 to induce ischemia in an iducible transgenic mouse model of Alzheimer's disease, APPsi:tTA, allowing for temporal control of APP gene expression. We induced the focal subclinical ischemic events in the absence of APP expression, thus prior to AD onset. T2 structural magnetic resonance imaging confirmed the volume and location of focal subclinical ischemic lesions to the medial prefrontal cortex. Following recovery from surgery and 7 weeks of APP expression, we found that two subclinical ischemic lesions resulted in a significant localized increase in amyloid load and in microglial activation proximal to the lesion. However, no differences were found in astrogliosis. A battery of behaviour tests was conducted, in which no significant differences were detected in activities of daily living and cognitive function between stroked and sham cohorts. Overall, our results demonstrated that APP expression was the sole driving force behind behavioural deficits. In conclusion, our results suggest that a history of two subclinical strokes prior to AD onset does not worsen early disease trajectory in a mouse model.</p>
neurosciences
What problem does this paper attempt to address?
This paper attempts to explore the impact of covert stroke on the surrounding pathological changes before the onset of Alzheimer's disease (AD), and whether this impact will lead to the exacerbation of cognitive dysfunction. Specifically, the researchers used an inducible transgenic mouse model (APPsi:tTA) to induce local sub - clinical ischemic events through endothelin - 1 (ET1), simulating the covert stroke that healthy middle - aged adults may experience. The main purpose of the study was to evaluate whether these covert strokes would accelerate the pathological changes in the surrounding areas before the onset of AD without causing a significant decline in cognitive function. ### Research Background 1. **The Relationship between Covert Stroke and AD**: Studies have shown that up to one - third of healthy middle - aged people may experience a covert stroke once in their lifetime. The risk of stroke survivors developing dementia is more than twice that of ordinary people. 2. **Sub - clinical Ischemia Model**: The study used the endothelin - 1 (ET1) model to induce local sub - clinical ischemia, which is a controllable and dose - dependent ischemia model. 3. **AD Model**: An inducible transgenic mouse model (APPsi:tTA) was used, which allows time - controlled expression of the APP gene, thereby simulating the early onset process of AD. ### Research Methods 1. **Animal Model**: Double - transgenic APPsi:tTA mice were used. These mice had APP gene expression inhibited by doxycycline at birth, and sub - clinical ischemia was induced by stereotactic injection of ET1 or saline (as a control) at 10 weeks of age. 2. **Behavioral Tests**: Behavioral tests were carried out before and after the operation to evaluate the ability of daily activities and cognitive function. 3. **Pathological Analysis**: Amyloid protein deposition and the activation of microglia and astrocytes were evaluated by immunofluorescence staining and T2 - weighted MRI. ### Main Findings 1. **Amyloid Protein Deposition**: After sub - clinical ischemia, the amyloid load in the perilesional area increased significantly, but there was no significant difference in the whole brain. 2. **Microglia Activation**: After sub - clinical ischemia, the coverage area of microglia in the perilesional area increased significantly, indicating that microglia were activated. 3. **Astrocyte Activation**: There was no significant change in the activation of astrocytes after sub - clinical ischemia. 4. **Behavioral Tests**: Although APP over - expression led to a decline in the ability of daily activities and cognitive function, sub - clinical ischemia itself did not cause significant behavioral changes. ### Conclusion The research results show that sub - clinical stroke does accelerate amyloid protein deposition and microglia activation in the perilesional area before the onset of AD, but does not cause a significant decline in cognitive function. This indicates that APP over - expression is the main driving factor for behavioral deficits, and sub - clinical stroke itself has a limited impact on the early course of AD. ### Formulas This article does not involve complex mathematical or physical formulas, but some statistical analysis methods are mentioned, such as ANOVA (analysis of variance) and Tukey’s Post - hoc test. These methods are used to evaluate the significant differences between different groups, for example: - **ANOVA**: It is used to compare the mean differences between multiple groups. \[ F=\frac{MS_{\text{between}}}{MS_{\text{within}}} \] where \(MS_{\text{between}}\) is the between - group mean square and \(MS_{\text{within}}\) is the within - group mean square. - **Tukey’s Post - hoc test**: It is used to further determine which groups have significant differences after ANOVA shows significant differences. \[ q = \frac{\bar{x}_i-\bar{x}_j}{\sqrt{MSE\left(\frac{1}{n_i}+\frac{1}{n_j}\right)}} \] where \(\bar{x}_i\) and \(\bar{x}_j\) are the means of two groups, \(MSE\) is the mean square error, and \(n_i\)